The U.S. Department of Health and Human Services Office of the Inspector General says the Centers for Medicare and Medicaid Services should monitor non-hospital 340B covered entities’ use of modifiers to identify 340B-priced drugs in Part B claims, as these
…
The fight over 340B contract pharmacy loomed large in stakeholders’ comments last week on a proposed federal regulation to revamp the 340B program’s administrative dispute resolution system.
Health care provider groups, citing manufacturers’ contract pharmacy policies, said they want the
…
The U.S. Senate committee with jurisdiction over 340B is officially under new leadership, with Bernie Sanders (I-Vt.) being seated as Health, Education, Labor, and Pensions chair last week and Bill Cassidy (R-La.) as ranking Republican.
The formal announcements had been
…
Pharmaceutical manufacturer GlaxoSmithKline said last week it would pay refunds for 340B overcharges occurring in the first quarter of 2021, including overcharges for blockbuster respiratory drugs Trelegy and Nucala.
The refund notice posted Feb. 2 on the U.S. Health
…
Drugmakers Lilly, Novartis, and United Therapeutics this week urged federal appeals courts in Chicago and Washington, D.C., to follow the lead of the appeals court in Philadelphia and uphold their restrictions on 340B providers’ use of contract pharmacies.
Lilly on
…
The Biden administration said on Monday that it plans to end the nationwide COVID-19 public health emergency on May 11. When the PHE ends, COVID-related 340B program flexibilities announced in March 2020 could end too.
The U.S. Health Resources and
…
The American Hospital Association yesterday asked to meet with the team of federal officials that will decide how the government will repay 340B hospitals for five years’ worth of illegal Medicare Part B drug reimbursement cuts. The amount of refunds
…
Covered entities may still use the 340B program under drug manufacturers’ conditions on the use of contract pharmacies, and while they “cannot squeeze as much revenue out of it as they once could, drug makers need not help them maximize
…
In his inaugural column for Verity Solutions, 340B Report Publisher and CEO Ted Slafsky offers insights “on what to expect in Washington, D.C., and the states in 2023 when it comes to the 340B program.”
Slafsky in the column makes
…*Sign up for news summaries and alerts from 340B Report